AEON Biopharma, Inc. (AEON) vs GT Biopharma, Inc. (GTBP)

AEON Biopharma, Inc. and GT Biopharma, Inc. are both Biotechnology companies. AEON Biopharma, Inc. and GT Biopharma, Inc. are of similar size ($9.4M and $9.4M). AEON Biopharma, Inc. has negative trailing earnings, so its P/E is not meaningful; GT Biopharma, Inc. trades at 0.8×. Across the 7 metrics below, GT Biopharma, Inc. leads on 4 and AEON Biopharma, Inc. on 3.

Valuation

Metric AEON GTBP Biotechnology median
P/E n/m 0.76 10.60
P/S n/m 114.39 9.40
P/B n/m 1.92 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 475.21 9.02
Earnings yield (2,455.56%) 130.83% (32.88%)
Free cash flow yield (150.03%) (207.77%) (23.13%)

Profitability

Metric AEON GTBP Biotechnology median
Gross margin — 41.67% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 350.00% 102.03% (51.96%)
Return on assets (621.70%) (176.27%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AEON GTBP Biotechnology median
Revenue growth (TTM) — (76.19%) 6.76%
EPS growth (last fiscal year) (105.42%) 3.75% 29.88%
Revenue growth, 5-year CAGR — 19.67% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AEON GTBP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.54 2.61 4.97
Net debt to EBITDA (2.48) 0.56 1.01

Dividend

Metric AEON GTBP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AEON GTBP Biotechnology median
Market cap 9.35m 9.36m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack